This paradoxical observation suggests that although the broader gefitinib response signature may confer protective effects, CCL2 specifically could drive tumor-associated macrophage (TAMs) recruitment, potentially counteracting therapeutic efficacy by remodeling the tumor microenvironment. This evidence concerns the gene CCL2 and neoplasm.